Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0I8LU
|
||||
Former ID |
DAP000845
|
||||
Drug Name |
Zuclopenthixol
|
||||
Synonyms |
Acuphase; CLOPENTHIXOL; Cisordinol; Clopenthixolum; Clopentixol; Clopixol; Zuclopenthixolum; Zuclopentixol; Alpha Clopenthixol; Zuclopenthixolum [Latin]; Zuclopentixol [Spanish]; Acuphase (TN); Alpha-Clopenthixol; Cisordinol (TN); Clopenthixol (USAN); Clopixol (TN); Zuclopenthixol (INN); Zuclopenthixol [BAN:INN]; (Z)-4-(3-(2-Chlorothioxanthen-9-ylidene)propyl)-1-piperazineethanol; 2-[4-[(3Z)-3-(2-chlorothioxanthen-9-ylidene)propyl]piperazin-1-yl]ethanol; 2-{4-[(3Z)-3-(2-chloro-10H-dibenzo[b,e]thiopyran-10-ylidene)propyl]piperazin-1-yl}ethanol; 2-{4-[3-(2-chloro-10H-dibenzo[b,e]thiopyran-10-ylidene)propyl]piperazin-1-yl}ethanol; 4-(3-(2-Chlorothioxanthen-9-ylidene)propyl)-1-piperazineethanol
|
||||
Drug Type |
Small molecular drug
|
||||
Therapeutic Class |
Antipsychotic Agents
|
||||
Company |
Lundbeck pharmaceutical company
|
||||
Structure |
Download2D MOL |
||||
Formula |
C22H25ClN2OS
|
||||
InChI |
InChI=1S/C22H25ClN2OS/c23-17-7-8-22-20(16-17)18(19-4-1-2-6-21(19)27-22)5-3-9-24-10-12-25(13-11-24)14-15-26/h1-2,4-8,16,26H,3,9-15H2/b18-5+
|
||||
InChIKey |
WFPIAZLQTJBIFN-BLLMUTORSA-N
|
||||
CAS Number |
CAS 53772-83-1
|
||||
PubChem Compound ID | |||||
PubChem Substance ID | |||||
ChEBI ID |
ChEBI:51364
|
||||
SuperDrug ATC ID |
N05AF05
|
||||
SuperDrug CAS ID |
cas=053772831
|
||||
Target and Pathway | |||||
Target(s) | D(2) dopamine receptor | Target Info | Antagonist | [534860], [535384] | |
References | |||||
Ref 542559 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7559). | ||||
Ref 550679 | Drug information of Zuclopenthixol, 2008. eduDrugs. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.